• Revenue of $6.0 billion (up 9.5%)
• Underlying EBITDA of $291 million (up 7.1%)
• Interim dividend of NZ 57.0 cents per share maintained
• Expects to generate Underlying EBITDA between $575 - $600 million in FY25

EBOS Group Ltd reported a strong performance in its half-year results, with revenue of $6.0 billion (up 9.5%) and underlying EBITDA of $291 million (up 7.1%). The Healthcare segment grew underlying EBITDA by 7.0%, benefiting from its leading market positions, while the Animal Care segment grew underlying EBITDA by 7.2%, driven by the strong performance of the branded business. The company made progress on its near-term growth strategies, including securing approximately $100 million in revenue from new pharmacy wholesale customers and achieving $15 million in cost savings. EBOS also completed three investments in the Medical Technology business in Southeast Asia, consistent with its strategy of growing in the region. The Board declared an interim dividend of NZ 57.0 cents per share, maintaining the same level as the prior period, reflecting the company's confidence in its future growth. EBOS reiterated its guidance that the Group expects to generate Underlying EBITDA between $575 - $600 million in FY25, implying growth of approximately 5-10% compared to the prior year.

EBOS reiterates its guidance that the Group expects to generate Underlying EBITDA between $575 - $600 million in FY25.

EBOS is pleased with the strong underlying earnings growth in the first half of FY25, driven by both organic growth and acquisitions. EBOS has demonstrated resilience and delivered underlying growth as it adapts positively to changing market dynamics, reflecting the defensive and diverse nature of the Group.